|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 546.80 INR | -2.56% |
|
-0.91% | +30.44% |
| 08-22 | IHH Healthcare Updates on Tokyo Court Case Over Fortis Acquisition | MT |
| 08-08 | Jefferies Adjusts Fortis Healthcare's Price Target to INR575 From INR545, Keeps at Buy | MT |
| Capitalization | 413B 4.92B 375B | P/E ratio 2025 * |
51.6x | P/E ratio 2026 * | 39.4x |
|---|---|---|---|---|---|
| Enterprise value | 415B 4.94B 376B | EV / Sales 2025 * |
5.29x | EV / Sales 2026 * | 4.56x |
| Free-Float |
64.76% | Yield 2025 * |
0.19% | Yield 2026 * | 0.22% |
More valuation ratios
* Estimated data
More news
Last Transcript: Fortis Healthcare Limited
More recommendations
More press releases
| 1 day | -2.56% | ||
| 1 week | -0.91% | ||
| Current month | -0.91% | ||
| 1 month | +12.45% | ||
| 3 months | +17.39% | ||
| 6 months | +37.61% | ||
| Current year | +30.44% |
1 week
537.40
569.90
1 month
485.00569.90
Current year
375.05569.90
1 year
313.80569.90
3 years
219.75569.90
5 years
113.10569.90
10 years
100.25569.90
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 18/03/19 | |
Daljit Singh
PSD | President | 71 | 31/08/02 |
| Director of Finance/CFO | - | 07/04/19 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 26/04/18 | |
Ravi Rajagopal
CHM | Chairman | 69 | 26/04/18 |
| Director/Board Member | 68 | 26/04/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 6 M€ | +6.07% | - | |
| 0.03% | 4 M€ | -4.41% | - | |
| 0.02% | 99 M€ | +1.85% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -2.56% | -0.91% | +62.67% | +98.44% | 4.92B | ||
| +1.75% | +4.50% | +5.45% | +26.64% | 13.74B | ||
| +2.48% | +5.26% | +11.68% | +4.76% | 13.42B | ||
| -2.00% | -4.02% | -49.89% | -65.07% | 12.21B | ||
| -0.40% | -0.30% | +37.34% | +41.62% | 11.83B | ||
| -1.85% | -1.49% | +31.13% | +15.32% | 9.22B | ||
| -1.73% | -1.53% | +54.97% | +83.27% | 8.45B | ||
| +0.08% | -4.12% | -18.06% | -42.88% | 6.09B | ||
| -1.16% | -1.92% | -7.94% | +6.81% | 5.43B | ||
| +0.74% | +2.65% | +14.21% | +112.57% | 4.23B | ||
| Average | -0.47% | +0.18% | +14.15% | +28.15% | 8.95B | |
| Weighted average by Cap. | -0.21% | +0.76% | +11.51% | +19.08% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 78.45B 935M 71.18B | 89.81B 1.07B 81.48B |
| Net income | 7.95B 94.75M 7.22B | 10.33B 123M 9.37B |
| Net Debt | 2.1B 25.04M 1.91B | -3.65B -43.48M -3.31B |
More financial data
* Estimated data
Employees
12,088
Calendar
07/11/2024
- Q2 2025 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/09/24 | 546.80 ₹ | -2.56% | 1,221,611 |
| 05/09/24 | 561.15 ₹ | +3.25% | 2,300,118 |
| 04/09/24 | 543.50 ₹ | -3.53% | 1,860,454 |
| 03/09/24 | 563.40 ₹ | +0.28% | 1,039,483 |
| 02/09/24 | 561.85 ₹ | +1.82% | 2,365,508 |
Delayed Quote NSE India S.E., September 06, 2024 at 12:43 pm
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
546.80INR
Average target price
543.20INR
Spread / Average Target
-0.66%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- FORTIS Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition